Policy· Brief · November 2, 2026, 5:00 PM ET

BioArctic says Novartis terminates collaboration agreement

BioArctic AB announced that Novartis Pharma AG has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025. The company will retain the full USD 30 million upfront payment and recognize the remaining unrecognized portion as revenue in 2026.

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation